KPV

What it is

KPV is a tiny natural fragment - just three amino acids, lysine-proline-valine - clipped from the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body makes for pigmentation and immune signaling. KPV keeps alpha-MSH's anti-inflammatory punch without needing the receptor that causes tanning: in mouse studies it calmed inflammation even in animals whose MC1 pigmentation receptor did not work, so its anti-inflammatory action runs through a different route - mainly switching off NF-kB, a master switch that turns on inflammatory genes throughout the body. What makes KPV unusual among peptides is that it can be absorbed straight through the gut wall using PepT1, a transporter built to carry small food-derived peptides into cells; most peptides this size get digested before they can do anything. That transporter is also why KPV research focuses so heavily on the gut: in mouse models of colitis (both a chemical-irritant model and an immune-cell-transfer model that mimics Crohn's-like inflammation), oral KPV in the drinking water measurably reduced inflammatory markers, sped weight recovery, and even blocked colon tumor formation in a long-term colitis-to-cancer mouse model - an effect that disappeared once the PepT1 transporter was knocked out, confirming the transporter is doing the work. All of that evidence is mouse and cell-culture data; there is no published human trial. The milligram/microgram self-injection or oral protocols circulating in peptide communities, including pairing KPV with GHK-Cu, BPC-157 and TB-500 in the 'KLOW' stack, are vendor and community convention extrapolated from that preclinical work, not doses established in people.

Dose ranges

Study-backed ranges carry a source you can open. Community ranges are widely reported but not clinically established - treat them as what people do, not as advice.

Reconstitution & storage

Vendor/community convention, not a clinical or manufacturer standard - no FDA-approved KPV drug product exists. Two different pairings show up across community guides: a 5 mg vial with 5 mL bacteriostatic water (about 1 mg/mL), or a 10 mg vial with 3 mL bacteriostatic water (about 3.33 mg/mL). Reconstituted product is typically measured on a U-100 insulin syringe (1 unit = 0.01 mL), so at 3.33 mg/mL each unit delivers roughly 33 mcg.

Common stacks

Interactions & cautions

No human drug-interaction trials exist for KPV, so nothing below is clinically confirmed - it is either reasoned pharmacology or secondary regulatory reporting. A community/compounding-pharmacy review of FDA materials lists open, unresolved safety questions rather than known risks: unknown effects in pregnancy and pediatric use, unknown behavior in people with cancer, autoimmune conditions, renal disease or hepatic impairment, unknown interactions with immunomodulatory medications, and general immunogenicity/impurity risk from unregulated injectable material. The same source reports that in July 2026 FDA's Pharmacy Compounding Advisory Committee (PCAC) gave a favorable recommendation toward adding KPV to the 503A Bulks List, but is explicit that this is advisory only, not FDA approval, and that further FDA rulemaking plus state-level requirements still apply; a direct fetch of FDA's own meeting page 404'd for us, so treat this as secondary reporting rather than a confirmed, current regulatory status. Because the Kannengiesser 2008 mouse study found KPV's anti-inflammatory effect held even in MC1R-deficient animals, KPV is not expected to carry the pigmentation/tanning effects associated with MC1R-agonist melanocortin peptides (e.g., Melanotan II) - but this is a mechanism-based inference from one study, not a dedicated human comparison. As with any unregulated peptide product, the biggest practical risk in community use is likely the product itself - contamination, mislabeling, or wrong concentration - none of which has been studied for KPV specifically.

Questions people ask

Sources

1. [1]PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation PMID 18061177studyKPV at 10 nM inhibited NF-kB and MAP kinase inflammatory signaling in intestinal epithelial cells via the PepT1 transporter, and 100 µmol/L KPV given orally in drinking water reduced DSS- and TNBS-induced colitis severity in mice, including roughly a 50% drop in colonic myeloperoxidase activity.
2. [2]Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease PMID 18092346studyIn DSS colitis and CD45RBhi T-cell transfer colitis mouse models, KPV treatment sped weight recovery and significantly reduced inflammatory infiltrates and colonic MPO activity, and rescued MC1R-deficient (MC1Re/e) mice from DSS colitis death - showing the effect is at least partly independent of the MC1 receptor.
3. [3]Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model PMID 27458604studyIn an AOM/DSS colitis-associated colorectal cancer mouse model, 100 µmol/L oral KPV in drinking water sharply reduced tumor number, size and overall colonic tumor burden in wild-type mice, but this protection was lost in PepT1-knockout mice, confirming the effect depends on PepT1-mediated uptake.
4. [4]KPV Dosage Chart, Schedule & Reconstitution ProtocolcommunityCommunity reconstitution/dosing reference describing a 10 mg KPV vial mixed with 3 mL bacteriostatic water (about 3.33 mg/mL), a titration schedule from 200 to 500 mcg subcutaneous once daily over 4-8 weeks, storage frozen at -20C lyophilized and refrigerated 2-8C once reconstituted, and an explicit disclaimer that no large randomized human trials support its IBD or dermatology dosing claims.
5. [5]Klow Dosage & Frequency Chart: 80mg ProtocolcommunityCommunity guide describing the KLOW blend as a fixed 50/10/10/10 mg vial (GHK-Cu/KPV/BPC-157/TB-500, 80 mg total), reconstituted in 2 mL bacteriostatic water, with a loading dose of 500 mcg KPV per injection 5x/week for weeks 1-4 and a 250 mcg maintenance dose 3x/week for weeks 5-12, and states no human clinical trials exist for the combination.
6. [6]KPV Peptide: Benefits, Inflammation Research & FDA StatuscommunityStates KPV is not FDA-approved, that FDA's Pharmacy Compounding Advisory Committee gave a favorable recommendation in July 2026 for KPV-related bulk substances toward the 503A Bulks List without this being final FDA approval, and lists unknowns around pregnancy, pediatric use, cancer, autoimmune disease, renal/hepatic impairment, and immunomodulator interactions as open safety questions.
7. [7]KPV Peptide: Anti-Inflammatory Tripeptide From Alpha-MSHcommunityDescribes KPV's anti-inflammatory action as working through NF-kB inhibition and PepT1-mediated transport into intestinal epithelial and immune cells (explaining oral gut activity), gives an alternate community reconstitution of 5 mg KPV with 5 mL bacteriostatic water (about 1 mg/mL) and an oral community dose of 500-1,500 mcg/day, and states long-term human safety data do not exist.